Exploring Rosiglitazone’s Potential to Treat Alzheimer’s Disease through the Modulation of Brain-Derived Neurotrophic Factor
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that debilitates over 55 million individuals worldwide. Currently, treatments manage and alleviate its symptoms; however, there is still a need to find a therapy that prevents or halts disease progression. Since AD has been labeled...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-7737/12/7/1042 |
| _version_ | 1797590193807556608 |
|---|---|
| author | Mackayla L. Nelson Julia A. Pfeifer Jordan P. Hickey Andrila E. Collins Bettina E. Kalisch |
| author_facet | Mackayla L. Nelson Julia A. Pfeifer Jordan P. Hickey Andrila E. Collins Bettina E. Kalisch |
| author_sort | Mackayla L. Nelson |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that debilitates over 55 million individuals worldwide. Currently, treatments manage and alleviate its symptoms; however, there is still a need to find a therapy that prevents or halts disease progression. Since AD has been labeled as “type 3 diabetes” due to its similarity in pathological hallmarks, molecular pathways, and comorbidity with type 2 diabetes mellitus (T2DM), there is growing interest in using anti-diabetic drugs for its treatment. Rosiglitazone (RSG) is a peroxisome proliferator-activated receptor-gamma agonist that reduces hyperglycemia and hyperinsulinemia and improves insulin signaling. In cellular and rodent models of T2DM-associated cognitive decline and AD, RSG has been reported to improve cognitive impairment and reverse AD-like pathology; however, results from human clinical trials remain consistently unsuccessful. RSG has also been reported to modulate the expression of brain-derived neurotrophic factor (BDNF), a protein that regulates neuroplasticity and energy homeostasis and is implicated in both AD and T2DM. The present review investigates RSG’s limitations and potential therapeutic benefits in pre-clinical models of AD through its modulation of BDNF expression. |
| first_indexed | 2024-03-11T01:17:03Z |
| format | Article |
| id | doaj.art-d077ccf875c641f78f7d3abea4052a23 |
| institution | Directory Open Access Journal |
| issn | 2079-7737 |
| language | English |
| last_indexed | 2024-03-11T01:17:03Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biology |
| spelling | doaj.art-d077ccf875c641f78f7d3abea4052a232023-11-18T18:24:46ZengMDPI AGBiology2079-77372023-07-01127104210.3390/biology12071042Exploring Rosiglitazone’s Potential to Treat Alzheimer’s Disease through the Modulation of Brain-Derived Neurotrophic FactorMackayla L. Nelson0Julia A. Pfeifer1Jordan P. Hickey2Andrila E. Collins3Bettina E. Kalisch4Department of Biomedical Sciences and Collaborative Specialization in Neuroscience Program, University of Guelph, Guelph, ON N1G 2W1, CanadaDepartment of Biomedical Sciences and Collaborative Specialization in Neuroscience Program, University of Guelph, Guelph, ON N1G 2W1, CanadaDepartment of Biomedical Sciences and Collaborative Specialization in Neuroscience Program, University of Guelph, Guelph, ON N1G 2W1, CanadaDepartment of Biomedical Sciences and Collaborative Specialization in Neuroscience Program, University of Guelph, Guelph, ON N1G 2W1, CanadaDepartment of Biomedical Sciences and Collaborative Specialization in Neuroscience Program, University of Guelph, Guelph, ON N1G 2W1, CanadaAlzheimer’s disease (AD) is a progressive neurodegenerative disorder that debilitates over 55 million individuals worldwide. Currently, treatments manage and alleviate its symptoms; however, there is still a need to find a therapy that prevents or halts disease progression. Since AD has been labeled as “type 3 diabetes” due to its similarity in pathological hallmarks, molecular pathways, and comorbidity with type 2 diabetes mellitus (T2DM), there is growing interest in using anti-diabetic drugs for its treatment. Rosiglitazone (RSG) is a peroxisome proliferator-activated receptor-gamma agonist that reduces hyperglycemia and hyperinsulinemia and improves insulin signaling. In cellular and rodent models of T2DM-associated cognitive decline and AD, RSG has been reported to improve cognitive impairment and reverse AD-like pathology; however, results from human clinical trials remain consistently unsuccessful. RSG has also been reported to modulate the expression of brain-derived neurotrophic factor (BDNF), a protein that regulates neuroplasticity and energy homeostasis and is implicated in both AD and T2DM. The present review investigates RSG’s limitations and potential therapeutic benefits in pre-clinical models of AD through its modulation of BDNF expression.https://www.mdpi.com/2079-7737/12/7/1042rosiglitazonebrain-derived neurotrophic factorAlzheimer’s diseaseclinical trialsperoxisome proliferator-activated receptor-gammatype 2 diabetes mellitus |
| spellingShingle | Mackayla L. Nelson Julia A. Pfeifer Jordan P. Hickey Andrila E. Collins Bettina E. Kalisch Exploring Rosiglitazone’s Potential to Treat Alzheimer’s Disease through the Modulation of Brain-Derived Neurotrophic Factor Biology rosiglitazone brain-derived neurotrophic factor Alzheimer’s disease clinical trials peroxisome proliferator-activated receptor-gamma type 2 diabetes mellitus |
| title | Exploring Rosiglitazone’s Potential to Treat Alzheimer’s Disease through the Modulation of Brain-Derived Neurotrophic Factor |
| title_full | Exploring Rosiglitazone’s Potential to Treat Alzheimer’s Disease through the Modulation of Brain-Derived Neurotrophic Factor |
| title_fullStr | Exploring Rosiglitazone’s Potential to Treat Alzheimer’s Disease through the Modulation of Brain-Derived Neurotrophic Factor |
| title_full_unstemmed | Exploring Rosiglitazone’s Potential to Treat Alzheimer’s Disease through the Modulation of Brain-Derived Neurotrophic Factor |
| title_short | Exploring Rosiglitazone’s Potential to Treat Alzheimer’s Disease through the Modulation of Brain-Derived Neurotrophic Factor |
| title_sort | exploring rosiglitazone s potential to treat alzheimer s disease through the modulation of brain derived neurotrophic factor |
| topic | rosiglitazone brain-derived neurotrophic factor Alzheimer’s disease clinical trials peroxisome proliferator-activated receptor-gamma type 2 diabetes mellitus |
| url | https://www.mdpi.com/2079-7737/12/7/1042 |
| work_keys_str_mv | AT mackaylalnelson exploringrosiglitazonespotentialtotreatalzheimersdiseasethroughthemodulationofbrainderivedneurotrophicfactor AT juliaapfeifer exploringrosiglitazonespotentialtotreatalzheimersdiseasethroughthemodulationofbrainderivedneurotrophicfactor AT jordanphickey exploringrosiglitazonespotentialtotreatalzheimersdiseasethroughthemodulationofbrainderivedneurotrophicfactor AT andrilaecollins exploringrosiglitazonespotentialtotreatalzheimersdiseasethroughthemodulationofbrainderivedneurotrophicfactor AT bettinaekalisch exploringrosiglitazonespotentialtotreatalzheimersdiseasethroughthemodulationofbrainderivedneurotrophicfactor |